111 related articles for article (PubMed ID: 36042628)
1. Correlations of ALD, Keap-1, and FoxO4 expression with traditional tumor markers and clinicopathological characteristics in colorectal carcinoma.
Huang P; Wang S; Wu Z; Zhou Z; Kuang M; Ren C; Qian X; Jiang A; Zhou Y; Wang X; Shao G
Medicine (Baltimore); 2022 Aug; 101(34):e30222. PubMed ID: 36042628
[TBL] [Abstract][Full Text] [Related]
2. Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer.
Wang Y; Kang XL; Zeng FC; Xu CJ; Zhou JQ; Luo DN
Pathol Res Pract; 2017 Jul; 213(7):766-772. PubMed ID: 28554751
[TBL] [Abstract][Full Text] [Related]
3. FOXO4 interacts with p53 TAD and CRD and inhibits its binding to DNA.
Mandal R; Kohoutova K; Petrvalska O; Horvath M; Srb P; Veverka V; Obsilova V; Obsil T
Protein Sci; 2022 May; 31(5):e4287. PubMed ID: 35481640
[TBL] [Abstract][Full Text] [Related]
4. Biophysical investigation of the dual binding surfaces of human transcription factors FOXO4 and p53.
Kim J; Ahn D; Park CJ
FEBS J; 2022 Jun; 289(11):3163-3182. PubMed ID: 34954873
[TBL] [Abstract][Full Text] [Related]
5. Forkhead box O4 transcription factor in human neoplasms: Cannot afford to lose the novel suppressor.
Lu C; Yang Z; Jiang S; Yang Y; Han Y; Lv J; Li T; Chen F; Yu Y
J Cell Physiol; 2019 Jun; 234(6):8647-8658. PubMed ID: 30515801
[TBL] [Abstract][Full Text] [Related]
6. FOXO4 Inhibits the Migration and Metastasis of Colorectal Cancer by Regulating the
Sun Y; Wang L; Xu X; Han P; Wu J; Tian X; Li M
Front Cell Dev Biol; 2021; 9():659731. PubMed ID: 34631691
[No Abstract] [Full Text] [Related]
7. FOXO4 ameliorates alcohol-induced chronic liver injury via inhibiting NF-κB and modulating gut microbiota in C57BL/6J mice.
Sang L; Kang K; Sun Y; Li Y; Chang B
Int Immunopharmacol; 2021 Jul; 96():107572. PubMed ID: 33798806
[TBL] [Abstract][Full Text] [Related]
8. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
Jin M; Long ZW; Yang J; Lin X
Pathol Oncol Res; 2018 Jan; 24(1):45-57. PubMed ID: 28188432
[TBL] [Abstract][Full Text] [Related]
9. Nrf2/P-glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer.
Sadeghi MR; Jeddi F; Soozangar N; Somi MH; Shirmohamadi M; Khaze V; Samadi N
Biomed Pharmacother; 2018 Aug; 104():458-464. PubMed ID: 29793178
[TBL] [Abstract][Full Text] [Related]
10. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability.
Brändstedt J; Wangefjord S; Nodin B; Eberhard J; Jirström K; Manjer J
BMC Cancer; 2014 May; 14():371. PubMed ID: 24885829
[TBL] [Abstract][Full Text] [Related]
11. Current perspective on the regulation of FOXO4 and its role in disease progression.
Liu W; Li Y; Luo B
Cell Mol Life Sci; 2020 Feb; 77(4):651-663. PubMed ID: 31529218
[TBL] [Abstract][Full Text] [Related]
12. C1q/tumor necrosis factor-related protein-3 (CTRP3) activated by forkhead box O4 (FOXO4) down-regulation protects retinal pericytes against high glucose-induced oxidative damage through nuclear factor erythroid 2-related factor 2 (Nrf2)/Nuclear factor-kappaB (NF-κB) signaling.
Zeng X; Peng Y; Wang Y; Kang K
Bioengineered; 2022 Mar; 13(3):6080-6091. PubMed ID: 35196182
[TBL] [Abstract][Full Text] [Related]
13. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus.
Chuang PY; Dai Y; Liu R; He H; Kretzler M; Jim B; Cohen CD; He JC
PLoS One; 2011; 6(8):e23566. PubMed ID: 21858169
[TBL] [Abstract][Full Text] [Related]
14. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.
Wangefjord S; Brändstedt J; Lindquist KE; Nodin B; Jirström K; Eberhard J
Diagn Pathol; 2013 Jan; 8():10. PubMed ID: 23337059
[TBL] [Abstract][Full Text] [Related]
15. Expression of FOXO4 Inhibits Cholangiocarcinoma Cell Proliferation
Intuyod K; Chomwong S; Thongpon P; Vaeteewoottacharn K; Pairojkul C; Pinlaor P; Pinlaor S
Anticancer Res; 2020 Dec; 40(12):6899-6905. PubMed ID: 33288583
[TBL] [Abstract][Full Text] [Related]
16. A new model for raf kinase inhibitory protein induced chemotherapeutic resistance.
Al-Mulla F; Bitar MS; Feng J; Park S; Yeung KC
PLoS One; 2012; 7(1):e29532. PubMed ID: 22279539
[TBL] [Abstract][Full Text] [Related]
17. FOXO4 and FOXD3 are predictive of prognosis in gastric carcinoma patients.
Li J; Jiang Z; Han F; Liu S; Yuan X; Tong J
Oncotarget; 2016 May; 7(18):25585-92. PubMed ID: 27027443
[TBL] [Abstract][Full Text] [Related]
18. FOXD3, frequently methylated in colorectal cancer, acts as a tumor suppressor and induces tumor cell apoptosis under ER stress via p53.
Xu M; Zhu J; Liu S; Wang C; Shi Q; Kuang Y; Fang X; Hu X
Carcinogenesis; 2020 Sep; 41(9):1253-1262. PubMed ID: 31784734
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-328-3p Protects Vascular Endothelial Cells Against Oxidized Low-Density Lipoprotein Induced Injury via Targeting Forkhead Box Protein O4 (FOXO4) in Atherosclerosis.
Qin X; Guo J
Med Sci Monit; 2020 Apr; 26():e921877. PubMed ID: 32329448
[TBL] [Abstract][Full Text] [Related]
20. Circ_UBR4 Knockdown Alleviates Oxidized Low-Density Lipoprotein-Provoked Growth and Migration of Human Vascular Smooth Muscle Cells by Acting on the miR-637/FOXO4 Pathway.
Ding Y; Tang T; Lu J; Wang J
J Cardiovasc Pharmacol; 2021 Oct; 78(4):534-543. PubMed ID: 34225339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
